New product: Daklinza (daclatasvir) film-coated tablets -

New product: Daklinza (daclatasvir) film-coated tablets
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Infection and infectious diseases | Liver disorders
Summary
Daclatasvir is an oral inhibitor of nonstructural protein 5A, a multifunctional protein that is an essential component of the hepatitis C virus (HCV) replication complex. It is licensed for use as part of combination therapy for the treatment of chronic HCV infection in adults.
UKMi comment
NICE intends to appraise daclatasvir through its Single Technology Appraisal process. A draft scope is available via the link below.
Related links: NICE draft scope